152
Views
7
CrossRef citations to date
0
Altmetric
Review

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date

, &
Pages 889-901 | Published online: 25 Sep 2020

References

  • Titmarsh GJ, Duncombe AS, McMullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis: how Common are Myeloproliferative Neoplasms? A Systematic Review and Meta-Analysis. Am J Hematol. 2014;89(6):581–587. doi:10.1002/ajh.23690
  • Harrison CN, McLornan DP. Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond. Hematology Am Soc Hematol Educ Program. 2017;2017(1):489–497. doi:10.1182/asheducation-2017.1.489
  • Naymagon L, Mascarenhas J. Myelofibrosis-Related Anemia: current and Emerging Therapeutic Strategies. HemaSphere. 2017;1(1):e1. doi:10.1097/HS9.0000000000000001
  • Tefferi A. Anemia in myelofibrosis—prevalence, the U2AF1 connection, new treatments. Blood Cancer J. 2017;7(12):648. doi:10.1038/s41408-017-0032-9
  • James C, Ugo V, Le Couédic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–1148. doi:10.1038/nature03546
  • Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–397. doi:10.1016/j.ccr.2005.03.023
  • Kralovics R, Passamonti F, Buser AS, et al. A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders. N Engl J Med. 2005;352(17):1779–1790. doi:10.1056/NEJMoa051113
  • Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–1061. doi:10.1016/S0140-6736(05)71142-9
  • Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. N Engl J Med. 2013;369(25):2379–2390. doi:10.1056/NEJMoa1311347
  • Celgene Corporation Press release. Aug. 16, 2019 – Summit, N.J. – Celgene Corporation (NASDAQ: CELG) Today Announced the U.S. Food and Drug Administration (FDA) Has Approved INREBIC® (Fedratinib) for the Treatment of Adult Patients with Intermediate-2 or High-Risk Primary or Secondary (Post-Polycythemia Vera or Post-Essential Thrombocythemia) Myelofibrosis; 2019.
  • Harrison C, Kiladjian -J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798. doi:10.1056/NEJMoa1110556
  • Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807. doi:10.1056/NEJMoa1110557
  • Palandri F, Elli EM, Polverelli N, et al. Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: role of Disease Status and Treatment Strategies in 214 Patients. Blood. 2018;132(Supplement 1):4277. doi:10.1182/blood-2018-99-116289
  • Tefferi A, Lasho TL, Jimma T, et al. One Thousand Patients With Primary Myelofibrosis: the Mayo Clinic Experience. Mayo Clinic Proc. 2012;87(1):25–33. doi:10.1016/j.mayocp.2011.11.001
  • Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–2901. doi:10.1182/blood-2008-07-170449
  • Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–1708. doi:10.1182/blood-2009-09-245837
  • Gangat N, Caramazza D, Vaidya R, et al. DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. JCO. 2011;29(4):392–397. doi:10.1200/JCO.2010.32.2446
  • Tefferi A, Guglielmelli P, Nicolosi M, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32(7):1631–1642. doi:10.1038/s41375-018-0107-z
  • Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ Version 2.0: mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J Clin Oncol. 2018;36(17):1769–1770. doi:10.1200/JCO.2018.78.9867
  • Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726–2731. doi:10.1038/leu.2017.169
  • Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. N Engl J Med. 2018;379(15):1416–1430. doi:10.1056/NEJMoa1716614
  • Pardanani A, Finke C, Abdelrahman RA, Lasho TL, Tefferi A. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. Am J Hematol. 2013;88(4):312–316. doi:10.1002/ajh.23406
  • Cervantes F, Alvarez-Larran A, Hernandez-Boluda J-C, et al. Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol. 2006;134(2):184–186. doi:10.1111/j.1365-2141.2006.06142.x
  • Tsiara SN, Chaidos A, Bourantas LK, Kapsali HD, Bourantas KL. Recombinant Human Erythropoietin for the Treatment of Anaemia in Patients with Chronic Idiopathic Myelofibrosis. Acta Haematol. 2007;117(3):156–161. doi:10.1159/000097463
  • McMullin MF, Harrison CN, Niederwieser D, et al. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, Phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Exp Hematol Oncol. 2015;4(1):26. doi:10.1186/s40164-015-0021-2
  • Thapaliya P, Tefferi A, Pardanani A, et al. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol. 2011;86(1):96–98. doi:10.1002/ajh.21892
  • Quintás-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis. JCO. 2009;27(28):4760–4766. doi:10.1200/JCO.2009.22.6548
  • Tefferi A, Al-Ali HK, Barosi G, et al. for the RESUME trialists. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia. 2017;31(4):896–902. doi:10.1038/leu.2016.300
  • Cervantes F, Isola IM, Alvarez-Larrán A, Hernández-Boluda J-C, Correa J-G, Pereira A. Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Ann Hematol. 2015;94(11):1791–1796. doi:10.1007/s00277-015-2435-7
  • Harrison CN, Patriarca A, Mascarenhas J, et al. Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients. Blood. 2019;134(Supplement_1):4164. doi:10.1182/blood-2019-128211
  • Mascarenhas J, Kremyanskaya M, Hoffman R, et al. MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or ‘Add-on’ to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. Blood. 2019;134(Supplement_1):670. doi:10.1182/blood-2019-127119
  • Gerds AT, Vannucchi AM, Passamonti F, et al. A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia. Blood. 2019;134(Supplement_1):557. doi:10.1182/blood-2019-122546
  • Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia. 2009;23(8):1441–1445. doi:10.1038/leu.2009.50
  • Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 2010;115(25):5232–5240. doi:10.1182/blood-2009-05-223727
  • Asshoff M, Petzer V, Warr MR, et al. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017;129(13):1823–1830. doi:10.1182/blood-2016-09-740092
  • Xin Y, Kawashima J, Weng W, Kwan E, Tarnowski T, Silverman JA. Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment. J Clin Pharm. 2018;58(4):522–532. doi:10.1002/jcph.1050
  • Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013;27(6):1322–1327. doi:10.1038/leu.2013.71
  • Pardanani A, Gotlib J, Roberts AW, et al. Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Leukemia. 2018;32(4):1034–1037. doi:10.1038/leu.2017.330
  • Tefferi A, Barraco D, Lasho TL, et al. Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood Cancer J. 2018;8(3):29. doi:10.1038/s41408-018-0067-6
  • Mesa RA, Kiladjian -J-J, Catalano JV, et al. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis. J Clin Oncol. 2017;35(34):3844–3850. doi:10.1200/JCO.2017.73.4418
  • Mesa RA, Catalano J, Cervantes F, et al. Dynamic and time-to-event analyses demonstrate marked reduction in transfusion requirements for janus kinase inhibitor-naïve myelofibrosis patients treated with momelotinib compared head to head with ruxolitinib. 2019 ASH Annual Meeting & Exposition. 2019.
  • Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018;5(2):e73–81. doi:10.1016/S2352-3026(17)30237-5